Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.46 |
| ▸ | RAF1 | P04049 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3117357 | 0.92 | BRAF (0.45) | BRAFRAF1P2RX3ROCK2ROCK1 | |
| SCHEMBL3123153 | 0.90 | BRAF (0.47) | BRAFRAF1ROCK2ROCK1PRKACA | |
| SCHEMBL3123899 | 0.89 | RAF1 (0.46) | BRAFRAF1ROCK2ROCK1PRKACA | |
| SCHEMBL3119170 | 0.89 | SCN9A (0.48) | BRAFRAF1P2RX3ROCK2ROCK1 | |
| SCHEMBL1644941 | 0.89 | RAF1 (0.47) | BRAFRAF1ROCK2ROCK1PRKACA | |
| SCHEMBL3121173 | 0.89 | RAF1 (0.42) | BRAFRAF1P2RX3ROCK2ROCK1 | |
| SCHEMBL3109097 | 0.88 | BRAF (0.53) | BRAFRAF1ROCK2ROCK1 | |
| SCHEMBL3127591 | 0.88 | BRAF (0.46) | BRAFRAF1ROCK2ROCK1PRKACA | |
| SCHEMBL3117289 | 0.87 | BRAF (0.46) | BRAFRAF1KDRROCK2ROCK1 | |
| SCHEMBL3121888 | 0.86 | ROCK1 (0.53) | BRAFRAF1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075967-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-7678804-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075967-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | TYMP, DPYD, CCNA2 | BRAF 90/4885RAF1 183/4885KDR 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.